Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams bought 12,000 shares of Geron stock in a transaction that occurred on Monday, November 16th. The shares were acquired at an average price of $0.94 per share, for a total transaction of $11,280.00. Following the completion of the transaction, the executive vice president directly owned 12,000 shares of the company’s stock, valued at $11,280. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Geron Stock Down 0.9%
Shares of NASDAQ:GERN opened at $0.99 on Thursday. The stock’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.40. The company has a current ratio of 6.31, a quick ratio of 4.61 and a debt-to-equity ratio of 0.53. Geron Corporation has a 12-month low of $0.84 and a 12-month high of $2.01. The firm has a market cap of $638.38 million, a price-to-earnings ratio of -12.39 and a beta of 0.62.
Institutional Trading of Geron
A number of hedge funds have recently made changes to their positions in GERN. Hsbc Holdings PLC acquired a new position in shares of Geron during the second quarter worth $25,000. LCM Capital Management Inc acquired a new stake in Geron during the 3rd quarter valued at $25,000. GTS Securities LLC grew its holdings in Geron by 71.6% during the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 9,921 shares in the last quarter. M Holdings Securities Inc. acquired a new stake in Geron during the 3rd quarter valued at $34,000. Finally, OneDigital Investment Advisors LLC acquired a new stake in Geron during the 2nd quarter valued at $38,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on GERN shares. Needham & Company LLC decreased their target price on shares of Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Wedbush dropped their price target on shares of Geron to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, October 28th. Finally, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Geron presently has a consensus rating of “Hold” and a consensus target price of $3.75.
Read Our Latest Analysis on Geron
About Geron
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Featured Articles
- Five stocks we like better than Geron
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
